Renal Cell Carcinoma
In a study of post-menopausal women, the highest quartile of lycopene intake was associated with a significant 39% decreased risk of renal cell carcinoma versus the lowest quartile.
98% of the renal tumors were controlled at 9 months after treatment.
Nephron-sparing approach is associated with a 56% decreased risk of postoperative end-stage renal disease versus radical surgery.
Low serum albumin levels increase the risk of death in patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Acute kidney injury developed in 23% of renal cell carcinoma patients receiving everolimus.
New study links statin use with a 52% improvement in 3-year disease-specific survival.
It preserves kidney function better than radical nephrectomy in patients with small- to medium-sized tumors, study finds.
Meta-analysis reveals a significantly increased risk of kidney stones only in male patients with kidney cancer.
Among surgically-treated renal cell carcinoma patients, diabetics have a 55% and 32% increased risk of cancer-specific and all-cause mortality.
Study shows that tumor flare resulting from discontinuation of sunitinib and pazopanib is associated with decreased overall survival.
Ultrasound surveillance for renal tumors should be performed on native and graft kidneys from 3 years after transplantation.
Are you more likely to perform partial rather than radical nephrectomy for tumors if robotic-assisted surgery is available?September 26, 2014
Availability of robotic-assisted surgery at a hospital was independently associated with greater use of partial nephrectomy.
Are you surprised that targeted therapeutics for metastatic renal cell carcinoma (RCC) have not improved survival?September 12, 2014
A study found that targeted therapeutic agents for treating metastatic RCC has not led to an improvement in survival rates.
Study also finds increase in overall cancer rate among African-American children and adolescents.
Other predictors include neurovascular disease, obesity, and surgical approach.
The 3-year survival rates for patients diagnosed during 2006-2007 were similar to those diagnosed during 2001-2005.
Study shows a 3.5 times increased risk of death from renal cancer in hemodialysis patients undergoing nephrectomy.
As body mass index increases, so does the risk of kidney and bladder cancers in men and stomach, ovarian, and colon cancers in women.
Increased abdominal adiposity is associated with a greater likelihood of clear-cell renal cell carcinoma.
Renal function is preserved better compared with radical nephrectomy even when tumors are larger than the traditional 4 cm cutoff.
Renal tumors occur at a frequency 7.5 times greater in lithium-treated patients than in the general population, French study shows.
At last follow-up, 41 of 43 patients who underwent partial nephrectomy did not require dialysis.
Patients with levels of 161.5 mg/dL or greater had a 43% decreased risk of death from renal cell carcinoma than those with lower levels.
The finding emerged from a French study of 213 patients with metastatic renal cell carcinoma.
Added to sunitinib, it prolongs progression-free and overall survival in patients with unfavorable-risk metastatic renal cell carcinoma.
The risk of cancer-specific death at 1 year was 48% and 23% for patients whose disease recurred at 3 months and 3 years, respectively.
The proportion of patients undergoing the procedure has stayed at 6%-7% annually.
Larger tumor size, male sex, and higher nephrometry score indicate a greater likelihood that a renal mass is malignant, researchers report.
The DISSRM score may be an easy-to-calculate surrogate for competing risk mortality.
Open procedures, preoperative dialysis, and higher ASA score were significant predictors of readmission after radical nephrectomy.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)